This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Flecainide

Authoring team

Flecainide is a class IC antiarrhythmic drug.

Flecainide should be used cautiously because:

  • it is moderately negatively inotropic
  • it is arrhythmogenic
  • it increases mortality post-MI

The summary of product characteristics must be consulted before using this drug.

Notes:

  • SCN5A gene polymorphism histidine-558-to-arginine (H558R) is more prevalent in patients with atrial fibrillation (AF) compared with the general population and its presence is associated with a more favourable response to flecainide treatment (1)

Reference:

  • Trincado Ave M, Brion M, Blanco-Verea A, et al.Prevalence and relevance of H558R in the efficacy and toxicity of flecainide in patients with atrial fibrillation: a cohort study.Heart Published Online First: 01 November 2024.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.